The Psychedelic Therapeutics and Drug Development Conference has been organized to bring together the world's leading researchers and leaders in academia and industry to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. This event will highlight the progress being made towards regulatory approval of a variety of psychedelics with the potential to treat various conditions, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.
Conference Themes:
Clinical trial design
Risk Evaluation and Mitigation Strategy (REMS)
Abuse potential
Practical use/indications/
DEA licensure and policy considerations
Targets for novel drug development
Dosage (micro/low/high)
Second generation psychedelic drug design
FDA regulatory guidance
Toxicology studies and considerations
Conference Themes:
Clinical trial design
Risk Evaluation and Mitigation Strategy (REMS)
Abuse potential
Practical use/indications/
DEA licensure and policy considerations
Targets for novel drug development
Dosage (micro/low/high)
Second generation psychedelic drug design
FDA regulatory guidance
Toxicology studies and considerations
